Spyre Therapeutics (SYRE) Times Interest Earned (2015 - 2026)
Spyre Therapeutics' (SYRE) quarterly Times Interest Earned came in at -$43.18 in Q1 2026, up 87.02% YoY from -$23.09 in Q1 2025, and up 91.24% on a QoQ basis from -$492.86 in Q4 2025.
Spyre Therapeutics (SYRE) Times Interest Earned (2015 - 2026) Analysis & Trends
Spyre Therapeutics (SYRE) has 12 years of Times Interest Earned data on file, last reported at -$43.18 in Q1 2026.
- Quarterly Times Interest Earned rose 87.02% year-over-year to -$43.18 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$190.76 (up 85.67% YoY) and the FY2025 annual result came in at -$1.04, up 18.69% from the prior year.
- Times Interest Earned improved to -$43.18 in Q1 2026, from -$492.86 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of -$0.37 in Q4 2023 to a low of -$2769.6 in Q3 2024.
- A 5-year average of -$418.73 and a median of -$154.69 in 2022 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2023 — Times Interest Earned jumped 99.64% — and 2025, when it sank 130998.11%.
- Tracing SYRE's Times Interest Earned over 5 years: stood at -$100.85 in 2022, then jumped by 99.64% to -$0.37 in 2023, then fell by 2.75% to -$0.38 in 2024, then slumped by 130998.11% to -$492.86 in 2025, then surged by 91.24% to -$43.18 in 2026.
- The last three Times Interest Earned figures came in at -$43.18 (Q1 2026), -$492.86 (Q4 2025), and -$1497.1 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Spyre Therapeutics | 9.13 Bn | 9.13 Bn | - | -16.75 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.75 |
| Mar 31, 2026 | -43.18 |
| Dec 31, 2025 | -492.86 |
| Sep 30, 2025 | -1,497.05 |
| Jun 30, 2025 | -274.08 |
| Mar 31, 2025 | -332.71 |
| Dec 31, 2024 | -0.38 |
| Sep 30, 2024 | -2,769.60 |
| Jun 30, 2024 | -65.60 |
| Mar 31, 2024 | -105.93 |
| Dec 31, 2023 | -0.37 |
| Sep 30, 2023 | -159.45 |
| Dec 31, 2022 | -100.85 |
| Sep 30, 2022 | -161.68 |
| Jun 30, 2022 | -122.53 |
| Mar 31, 2022 | -154.69 |
| Dec 31, 2021 | -62.32 |
| Sep 30, 2021 | -1,193.71 |
| Jun 30, 2021 | -372.50 |
| Mar 31, 2021 | -18,209.00 |